Effects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus–Associated Wasting | Zendy

Viva Tai | Zendy; Morris Schambelan | Zendy; Heather A. Algren | Zendy; Clara Shayevich | Zendy; Kathleen Mulligan | Zendy

Open Access

Effects of Recombinant Human Growth Hormone on Fat Distribution in Patients with Human Immunodeficiency Virus–Associated Wasting

Author(s) -

Viva Tai,

Morris Schambelan,

Heather A. Algren,

Clara Shayevich,

Kathleen Mulligan

Publication year - 2002

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/343051

Subject(s) - wasting , medicine , lean body mass , placebo , recombinant dna , cachexia , endocrinology , trunk , fat distribution , wasting syndrome , sarcopenia , human growth hormone , human immunodeficiency virus (hiv) , hormone , growth hormone , adipose tissue , virology , body weight , biology , pathology , biochemistry , ecology , alternative medicine , cancer , gene

In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research